Nuohe New Yuan acquires Southeast Asian manufacturing base, further expanding global presence

Invests approximately $50 million to strengthen fermentation production capacity, supporting the company’s long-term growth strategy

Danish company Lymby April 8, 2026 /PRNewswire/ – Novo Nordisk today announced that it has signed an agreement with Meihua Group to acquire a production facility located in Rayong Province, Thailand, for approximately $50 million. This acquisition will further expand Novo Nordisk’s business layout in Southeast Asia and enhance the company’s ability to serve global customers.

Expansion into Asian markets is an important part of Novo Nordisk’s GROW strategy for 2030. Currently, emerging markets account for about one-third of the company’s sales, and it is expected that their growth rate will continue to be faster than that of developed markets. By investing in manufacturing bases with geographic advantages, Novo Nordisk further strengthens its unique global multi-purpose production system, enabling it to meet the needs of local and global markets more efficiently.

The acquired production base has advanced fermentation capabilities and can be continuously expanded as future needs evolve to support the company’s long-term growth plans, including the production of human milk oligosaccharides (HMO). Novo Nordisk plans to continue increasing investment in the coming years to fully unlock the development potential of this base and build a robust, efficient operating system. The company expects that the base will achieve commercial operations in 2027.

Novo Nordisk Chief Operating Officer Anders Lund said:

“Strengthening our manufacturing footprint in Southeast Asia is an important step for Novo Nordisk to drive long-term development. One of the core elements of the GROW strategy is to continuously build a resilient and rapidly responsive global supply network to support the company’s long-term growth goals. By continuously expanding and upgrading world-class manufacturing capabilities, we can be closer to the markets in this rapidly growing region, serve customers more efficiently, and create greater value for them.”

Continuously advancing capacity construction to improve the global resilience layout

The acquisition of the Rayong production base is one of several investments Novo Nordisk has advanced in recent years to enhance global production capacity and operational resilience. By continuously optimizing its global manufacturing layout, the company is better able to serve local customers and drive business growth. As part of this strategy, Novo Nordisk has been continuously expanding production facilities in places such as Franklin, North Carolina, United States; Taicang and Tianjin, China; Araucária, Brazil; and West Allis, Wisconsin, United States.

Within the current development strategy cycle targeting 2030, Novo Nordisk expects to continue increasing growth-oriented capital expenditures to meet the ever-growing demand from customers and consumers for bio solutions.